Oncolytics Biotech Inc. (NASDAQ:ONCY) won FDA Fast Track for pelareorep plus a checkpoint inhibitor in 2L+ squamous cell anal cancer after GOBLET showed ~30% ORR, 15.5‑month DOR and 82% 12‑month OS, even as NASDAQ:ONCY faces a bid-price compliance notice and must regain $1.00 by Jan 19, 2027.
Previous Week Recap
- Oncolytics Biotech Inc. FDA Fast Track: Oncolytics Biotech (ONCY) got FDA Fast Track for pelareorep plus a checkpoint inhibitor in 2L+ squamous cell anal cancer; GOBLET showed ~30% ORR, 15.5‑month DOR, 82% 12‑month OS.
- Oncolytics Biotech Inc. Nasdaq Notice: Oncolytics Biotech (ONCY) got a Nasdaq notice for falling below the $1.00 minimum bid for 30 business days. Company has until Jan 19, 2027 to regain compliance; trading continues.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.